pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen S.p.A.
Philogen S.p.A is a pharma organization headquartered in SIENA, IT. Primary therapeutic focus areas include Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma, locally advance
Phase 2 · small molecule · Glioblastoma
Fibromun (Temozolomide SUN 100 mg hard capsules) is an oral small-molecule antineoplastic agent developed by Philogen S.p.A. for the treatment of glioblastoma. The program is currently in Phase 2 development. Temozolomide is an established alkylating agent with a well-characterized mechanism of action in oncology; it i
Internal code PH-L19TNFTMZ-01/20
Fibromun (Temozolomide SUN 100 mg hard capsules) is an oral small-molecule antineoplastic agent developed by Philogen S.p.A. for the treatment of glioblastoma. The program is currently in Phase 2 development. Temozolomide is an established alkylating agent with a well-characterized mechanism of action in oncology; it is being evaluated in combination with L19TNF, a tumor-targeting human antibody-cytokine fusion protein, plus standard chemoradiotherapy in patients with newly diagnosed glioblastoma. The combination approach aims to enhance therapeutic efficacy by targeting tumor vasculature and immune activation alongside conventional chemotherapy. Temozolomide itself has been approved across major markets (US, EU, Australia) for over two decades, with multiple generic and branded formulations available. The current Phase 2 study (NCT identifier 2024-516357-46-00) is designed to evaluate safety and efficacy of this combination regimen. Philogen's strategy appears focused on repositioning temozolomide within a novel combination context to improve outcomes in newly diagnosed glioblastoma, a disease with significant unmet medical need despite standard-of-care chemoradiotherapy.
Glioblastoma remains one of the most aggressive and lethal primary brain tumors, with median overall survival of approximately 14–15 months despite maximal surgical resection, radiation, and chemotherapy. Standard-of-care treatment with temozolomide-based chemoradiotherapy has shown incremental benefit over radiation alone but leaves substantial room for improvement. The addition of L19TNF, a vascular-targeting immunomodulatory agent, represents a mechanistically distinct approach to enhance anti-tumor immunity and disrupt the immunosuppressive tumor microenvironment. This combination strategy addresses a critical unmet need: improving survival and quality of life for newly diagnosed glioblastoma patients who currently face poor prognosis despite aggressive multimodal therapy. From a market perspective, glioblastoma affects approximately 10,000–15,000 new patients annually in the US alone, representing a significant patient population for novel therapeutic approaches. The competitive landscape includes checkpoint inhibitors, targeted therapies, and other immunomodulatory agents, but combination strategies that integrate vascular targeting with conventional chemotherapy remain limited. Successful Phase 2 data could position this regimen as a meaningful advancement in first-line glioblastoma treatment, with potential for accelerated regulatory pathways given the unmet need. Commercial significance is substantial given the high treatment costs and limited alternatives in this indication.
Drug Class: Antineoplastic and immunomodulating agent (ATC L01)
Modality: Small molecule (oral alkylating agent)
Route of Administration: Oral
Active Pharmaceutical Ingredient: Temozolomide
Mechanism of Action: Not yet disclosed in the facts provided; however, temozolomide is a well-established imidazotetrazine derivative that functions as an alkylating agent, methylating DNA and inducing apoptosis in rapidly dividing cells.
Target: Not yet disclosed in the facts provided.
Related Therapies: Temozolomide is available under multiple brand names (APO-TEMOZOLOMIDE and others) and is manufactured by numerous sponsors including Merck Sharp & Dohme, Sun Pharmaceutical, Accord Healthcare, Teva, Sandoz, and others across approved markets.
First Approval: Temozolomide was first approved in Australia on 2000-02-01 and has been approved in the EU and US for over two decades, with multiple authorizations and generic formulations.
Patent Status: Not yet disclosed in the facts provided.
Also known as: GBM, GBM (glioblastoma), WHO grade IV glioma, glioblastoma (disease), glioblastoma multiforme, glioblastoma multiforme (disease)
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)
ClinicalTrials.gov lists 877 registered studies for Glioblastoma (AACT aggregate).
Phase breakdown: NA (252), PHASE2 (223), PHASE1 (206), PHASE1/PHASE2 (86), EARLY_PHASE1 (49), PHASE3 (45), PHASE2/PHASE3 (11), PHASE4 (5)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0018177), Orphanet — glioblastoma, NCT00001148, NCT00001171, NCT00009035, NCT00028158, NCT00029783, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2 combination study ongoing
Active Phase 2 evaluation of L19TNF plus standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma patients (NCT 2024-516357-46-00).
The competitive landscape for glioblastoma treatment includes multiple approved agents across different therapeutic classes. The facts list several competitors with approved status, though specific mechanisms and glioblastoma indications are not detailed for most entries. Notably, temozolomide itself is available from multiple manufacturers (Merck Sharp & Dohme, Sun Pharmaceutical, Accord Healthcare, Teva, Sandoz, and others), indicating a mature, competitive generic market. Other approved oncology agents listed (IMBRUVICA, AFINITOR, KYPROLIS, VYXEOS LIPOSOMAL, OFEV) represent checkpoint inhibitors, mTOR inhibitors, proteasome inhibitors, and other modalities, though their specific roles in glioblastoma are not disclosed in the facts. Pfizer Australia and Janssen-Cilag are noted as competitors with approved products. The Philogen strategy—combining L19TNF (a vascular-targeting immunomodulator) with standard temozolomide chemoradiotherapy—appears differentiated from single-agent approaches and may offer a mechanistic advantage in addressing both tumor vasculature and immune activation. However, without detailed competitive mechanism-of-action data, direct head-to-head positioning cannot be fully assessed from the facts provided.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| PFIZER AUSTRALIA PTY LTD | Pfizer Australia Pty Ltd | — | approved |
| IMBRUVICA | Janssen-Cilag Pty Ltd | — | approved |
| AFINITOR | Novartis Pharmaceuticals | — | approved |
| LYSODREN | S.A. | — | approved |
| INLYTA | Pfizer Australia Pty Ltd | — | approved |
| LYNOZYFIC | Regeneron UK Limited | — | approved |
| VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS) | Jazz Pharmaceuticals Ireland Limited | — | approved |
| KYPROLIS | Amgen | — | approved |
| UNITUXIN | United Therapeutics Europe Ltd | — | approved |
| PACLITAXEL ACCORD | Accord Healthcare Pty. | — | approved |
| OFEV | Boehringer Ingelheim Pty Ltd | — | approved |
| ARX-IMATINIB | Alphapharm Pty Ltd | — | approved |
| CARMUSTINE | — | Glutathione reductase inhibitor | Approved |
| BEVACIZUMAB | — | Vascular endothelial growth factor A inhibitor | Approved |
| TRABEDERSEN | — | Transforming growth factor beta-2 mRNA antisense inhibitor | Phase 3 |
| TOFACITINIB | — | Janus Kinase (JAK) inhibitor | Phase 3 |
| RINDOPEPIMUT | — | Epidermal growth factor receptor erbB1 vaccine antigen | Phase 3 |
| OMBIPEPIMUT-S | — | Wilms tumor protein vaccine antigen | Phase 3 |
| NIVOLUMAB | — | Programmed cell death protein 1 inhibitor | Phase 3 |
| NIMOTUZUMAB | — | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: Temozolomide is approved via multiple ANDA and NDA applications (NDA021029, NDA022277, and 16 ANDA approvals including ANDA078879, ANDA201528, ANDA201742, ANDA203490, ANDA203691, ANDA203898, ANDA203959, ANDA204159, ANDA204639, ANDA205227, ANDA206309, ANDA206413, ANDA206750, ANDA207658, ANDA210030, ANDA213328). Sponsors include Accord Healthcare, Amneal Pharmaceuticals, Ani Pharmaceuticals, Apotex, Chartwell, Chemi SPA, Deva Holding, Eirgen, Extrovis, Heritage, Hetero Labs, Merck Sharp Dohme, Nivagen Pharmaceuticals, Rising, Sun Pharmaceutical, Watson Labs/Teva, and Zydus Pharmaceuticals.
European Union: Temozolomide is approved with 8 EMA product numbers (EMEA/H/C/000229, EMEA/H/C/001124, EMEA/H/C/001125, EMEA/H/C/001126, EMEA/H/C/001127, EMEA/H/C/001128, EMEA/H/C/002198, EMEA/H/C/006169). Marketing authorization holders include Accord Healthcare, Hexal AG, Merck Sharp & Dohme B.V., ORPHELIA Pharma, Sandoz GmbH, Sun Pharmaceutical Industries Europe B.V., Teva B.V., and medac GmbH. Recent authorisation dates: 02/05/2025, 06/11/2025, 10/07/2025.
Australia: Temozolomide is approved with PBS codes 10062N, 2438H, 8378Y, 8379B, 8380C, 8381D, 8819E, 8820F, 8821G, 9361Q. Sponsors include Alphapharm Pty Ltd, Apotex Pty Ltd, Juno Pharmaceuticals Pty Ltd, and Merck Sharp & Dohme (Australia) Pty Ltd. First listed dates: 2000-02-01, 2005-06-01, 2009-01-01.
China: Temozolomide is in clinical trials status; NCT05457829 is referenced.
Fibromun Program Status: The Phase 2 combination study (NCT 2024-516357-46-00) is active. Regulatory pathway for the L19TNF combination regimen is not yet disclosed.
Fibromun (Temozolomide SUN 100 mg hard capsules) is being investigated in Phase 2 clinical trials for the treatment of newly diagnosed glioblastoma, in combination with L19TNF (a tumor-targeting antibody-cytokine fusion protein) and standard chemoradiotherapy.
Fibromun as a branded combination product is not yet approved. Temozolomide, the active ingredient, is approved by the FDA via multiple generic and branded formulations. The Phase 2 combination study with L19TNF is ongoing.
Temozolomide is an alkylating agent that methylates DNA, inducing apoptosis in rapidly dividing cancer cells. The exact mechanism of action for the Fibromun formulation is not yet disclosed in available facts.
Fibromun is developed by Philogen S.p.A., an Italian pharmaceutical company. The formulation is Temozolomide SUN 100 mg hard capsules, with Sun Pharmaceutical involved in manufacturing.
Fibromun is being studied for newly diagnosed glioblastoma, a highly aggressive primary brain tumor, in combination with L19TNF and standard chemoradiotherapy.
Fibromun is currently in Phase 2 clinical development. The active study (NCT 2024-516357-46-00) is evaluating safety and efficacy of the combination regimen.
L19TNF is a tumor-targeting human antibody-cytokine fusion protein designed to target tumor vasculature and enhance immune activation. It is combined with temozolomide to improve therapeutic efficacy in glioblastoma beyond standard chemoradiotherapy alone.
Yes, temozolomide is approved in the European Union under 8 EMA product numbers with multiple marketing authorization holders including Merck Sharp & Dohme, Accord Healthcare, Sandoz, Teva, and others.
Yes, temozolomide is approved in Australia with PBS codes and has been listed since 2000. Multiple sponsors including Alphapharm, Apotex, Juno Pharmaceuticals, and Merck Sharp & Dohme hold approvals.
Fibromun is administered orally as a 100 mg hard capsule formulation.
Specific glioblastoma competitors are not detailed in the facts. However, temozolomide itself is available from multiple manufacturers (Merck, Sun Pharma, Accord, Teva, Sandoz, others), and other approved oncology agents may be used in glioblastoma treatment.
The expected completion date for the Phase 2 study (NCT 2024-516357-46-00) is not yet disclosed in available facts.
Glioblastoma has poor prognosis despite standard-of-care chemoradiotherapy, with median overall survival around 14–15 months. New therapeutic approaches that improve survival and quality of life are urgently needed.
Fibromun is a branded formulation of temozolomide (Temozolomide SUN 100 mg) developed by Philogen in combination with L19TNF. Temozolomide itself is available as both branded and generic products globally.
Temozolomide is classified as an antineoplastic and immunomodulating agent (ATC code L01), specifically an alkylating agent used in cancer chemotherapy.
No development partner is disclosed in the available facts. Philogen S.p.A. is listed as the sole sponsor of the program.
The internal program code is PH-L19TNFTMZ-01/20, assigned by Philogen S.p.A.
Fibromun, Temozolomide SUN 100 mg hard capsules → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: Philogen's approach combines a mature, well-tolerated chemotherapy (temozolomide) with a novel vascular-targeting immunomodulator (L19TNF), potentially addressing two key limitations of standard-of-care: inadequate immune activation and tumor vascular immunosuppression. This combination strategy may offer a differentiated mechanism compared to checkpoint inhibitor monotherapies or other single-agent approaches.
Development Risk: Phase 2 is an early stage for a combination regimen; success will depend on demonstrating improved efficacy over standard chemoradiotherapy without unacceptable toxicity. The immunomodulatory component adds complexity to safety profiling.
Competitive Implications: Temozolomide is a crowded generic market with 17+ approved manufacturers globally. The value proposition rests entirely on the L19TNF combination benefit. If Phase 2 data are positive, the regimen could capture market share from standard chemoradiotherapy, particularly if it shows survival or quality-of-life benefits in newly diagnosed patients.
Regulatory Pathway: Glioblastoma is a serious condition with high unmet need; accelerated regulatory pathways (Breakthrough Therapy, Fast Track) may be available if Phase 2 demonstrates clinically meaningful benefit. EMA and FDA both have incentive programs for oncology combinations addressing unmet needs.
Future Catalysts: Phase 2 data readout (timing not disclosed); potential Phase 3 initiation; regulatory feedback meetings; biomarker or patient selection studies to optimize patient populations.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.